Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

Purpose This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast cancer (MBC).Methods At 40 si...

Full description

Bibliographic Details
Main Authors: Sung-Bae Kim, Hope S Rugo, Sara A Hurvitz, Hong-Tai Chang, Chiun-Sheng Huang, Su-Hua Lee, Jung-Tung Hung, Shir-Hwa Ueng, Shin-Cheh Chen, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Richard B Schwab, James L Murray, Hsien-Kun Chang, Chwen-Cheng Chen
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000342.full

Internet

https://jitc.bmj.com/content/8/2/e000342.full

Similar Items